What is Perrigo Company's pain & sleep — net sales?

Perrigo Company (PRGO) reported pain & sleep — net sales of $124.6M in Q2 2026.

What does pain & sleep — net sales mean?

This metric represents the total revenue generated from the sale of over-the-counter pain relief and sleep aid products within the company's consumer healthcare portfolio. It reflects the market demand for self-care solutions in the analgesic and sleep-support categories, serving as a key indicator of segment-specific growth and consumer brand loyalty. Tracking this figure allows investors to assess the performance of the company's therapeutic offerings against broader consumer health trends.

Perrigo Company (PRGO) Pain & Sleep — Net Sales

Screener

Other product segments

Oral Care

$354.4M-5.4%

Upper Respiratory

$178.4M-1.6%

Skin Health

$161.8M—

Healthy Lifestyle

$157.8M+2.0%

Digestive Health

$115.7M-3.4%

Women's Health

$64.8M+3.3%

Similar metrics at other companies

LOWPaint Sales — Net Sales

$1.25B+0.4%

HDPaint — Net Sales

$2.74B-1.9%

OECSpain — Net Sales

$11.9M-10.7%

AVN

AVNSSurgical pain and recovery — Net Sales

$21.8M-11.0%

GISPet — Net Sales

$746.6M+5.8%

AVN

AVNSTotal Pain Management and Recovery — Net Sales

$56.3M+0.2%

Other financials

Income statement

See full

Revenue$1.0B-3.2%

Gross profit$313.9M-13.5%

Operating income$23.5M-48.2%

Net income$74.5M+987%

EPS (diluted)$0.53+983%

Balance sheet

See full

Cash & equivalents$399.7M-12.0%

Total debt$3.5B-10.3%

Total equity$2.5B-43.7%

Total assets$7.6B-24.6%

Cash flow

See full

Operating cash flow-$113.6M-76.1%

CapEx$14.3M-25.5%

Free cash flow-$127.4M-41.6%

Valuation

See full

Market cap$1.74B-46.4%

Enterprise value$4.82B-27.7%

P/S0.4×-0.3×

Profitability

See full

Gross margin33.3%-2.5pp

Operating margin-37.7%-44.3pp

Net margin-41.9%-43.9pp

FCF margin4.2%-2.0pp

Returns & leverage

See full

Return on equity-49.6%-51.6pp

Debt / equity1.4×+0.5×

Current ratio2.3×0.0×

Where this comes from

Reported directly by Perrigo Company in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Perrigo Company’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 1:44 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001585364-26-000145

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025	Six Months Ended / June 27, 2026	Six Months Ended / June 28, 2025
Upper Respiratory	$178.4	$181.3	$375.7	$396.0
Digestive Health	115.7	119.8	212.4	232.6
Healthy Lifestyle	157.8	154.7	300.6	311.7
Pain & Sleep	124.6	142.8	231.2	272.5
Total Self Care	$576.6	$598.6	$1,119.9	$1,212.8
Specialty Care
Skin Health	$161.8	$170.3	$313.7	$319.9
Women's Health	64.8	62.7	119.9	112.3

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Perrigo Company's pain & sleep — net sales?: Perrigo Company (PRGO) reported pain & sleep — net sales of $124.6M in Q2 2026.
What does pain & sleep — net sales mean?: This metric represents the total revenue generated from the sale of over-the-counter pain relief and sleep aid products within the company's consumer healthcare portfolio. It reflects the market demand for self-care solutions in the analgesic and sleep-support categories, serving as a key indicator of segment-specific growth and consumer brand loyalty. Tracking this figure allows investors to assess the performance of the company's therapeutic offerings against broader consumer health trends.